Posts tagged clinical trials
Canadian scientists discover new antibiotic

Canadian scientists say they have discovered the first new antibiotic in three decades, and that their research suggests it may potentially be effective at killing two worrisome superbugs: Pseudomonas aeruginosa and Neisseria gonorrhoea.

Read More
Histogenics cartilage data published

Histogenics (NASDAQ:HSGX) announced the online peer-reviewed publication in the Journal of Orthopaedic Research that analyzes mechanical properties of tissue engineered cartilage based on work done as part of a sponsored-research agreement between Histogenics and Dr. Lawrence Bonassar at Cornell University. 

Read More
HCW assumes coverage of DURECT at buy

H.C. Wainwright has assumed coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and $3 price target. The stock was quoted at $1.02 in afternoon trading on Feb. 28.

Read More
Soricimed publishes Phase 1 results of SOR-C13

Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Read More
Mass. Life Sciences launches ramp-up program

The Massachusetts Life Sciences Center (MLSC) has launched the Massachusetts Ramp-Up Program (MassRamp), a new program that will provide grant funding to promising early-stage life sciences companies.

Read More
3DS raises $3.9-million in oversubscribed private placement

3D Signatures (TSX-V:DXD) issued 5,187,618 units under a brokered private placement at a price of 75 cents a unit for gross proceeds of about $3.9-million, including a partial exercise of an over-allotment option.

Read More
FDA grants orphan drug status to Soricimed’s SOR-C13

The FDA has granted orphan drug designation to closely-held Soricimed Biopharma’s peptide, SOR-C13, for the treatment of pancreatic cancer, following a similar designation for ovarian cancer

In a statement, Paul Gunn, president and CEO of Soricimed, said receiving orphan drug status in both ovarian and pancreatic cancer highlights the unmet medical need and the potential of SOR-C13 to address these devastating cancers.

Read More
Antibe posts positive Phase 2 results in OA

Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) reported positive results from a Phase 2 study of ATB-346 in osteoarthritis (OA).

Twelve patients with OA of the knee were treated once daily for 10 days with ATB-346 at a dose of 250 mg, a dose that contains one-sixth of the typical daily dose of naproxen for treating OA.

Read More
Ocular Therapeutix gets complete response letter

Ocular Therapeutix (NASDAQ:OCUL) received a complete response letter (CRL) from the FDA about its NDA for DEXTENZA for intracanalicular use in the treatment of ocular pain occurring after ophthalmic surgery.

Concerns raised by the FDA pertain to deficiencies in manufacturing process and controls identified during a pre-NDA approval inspection of the company’s manufacturing facility. The FDA’s letter did not provide any details as to which manufacturing deficiencies remain open since the last response submitted by the company.

Read More
ContraVir Pharma to merge with Ciclofilin Pharma

ContraVir Pharmaceuticals (NASDAQ:CTRV) has entered into a definitive merger agreement with closely-held Ciclofilin Pharmaceuticals.

Under the accord, ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments, which will be allocated among the holders of Ciclofilin common stock.

Read More
Incyte to acquire ARIAD’s EU operations, in-license Iclusig

Incyte (NASDAQ:INCY) has agreed to acquire ARIAD Pharmaceuticals’ (NASDAQ:ARIA) European operations. At the expected June 1 closing of the transaction, Incyte will obtain an exclusive license to develop and commercialize Iclusig in Europe and other select countries.

The agreement to divest its European operations and out-license Iclusig in Europe will enable ARIAD to focus its promotion of Iclusig on the highly valuable U.S. market, while strengthening its financial position and maintaining important optionality through a potential buy-back provision for the Iclusig license rights in the event of a change-in-control of ARIAD.

Read More